NasdaqCM - Nasdaq Real Time Price USD

Cyclacel Pharmaceuticals, Inc. (CYCC)

Compare
0.9801 +0.1201 (+13.97%)
As of 1:07 PM EDT. Market Open.
Loading Chart for CYCC
DELL
  • Previous Close 0.8600
  • Open 0.8600
  • Bid 0.7280 x 200
  • Ask 1.1300 x 200
  • Day's Range 0.8578 - 1.0500
  • 52 Week Range 0.7500 - 11.4000
  • Volume 123,217
  • Avg. Volume 52,543
  • Market Cap (intraday) 1.935M
  • Beta (5Y Monthly) 0.51
  • PE Ratio (TTM) --
  • EPS (TTM) -15.3100
  • Earnings Date Nov 11, 2024 - Nov 15, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 11.00

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

www.cyclacel.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CYCC

View More

Performance Overview: CYCC

Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CYCC
63.29%
S&P 500
22.21%

1-Year Return

CYCC
89.46%
S&P 500
34.70%

3-Year Return

CYCC
98.83%
S&P 500
30.37%

5-Year Return

CYCC
99.12%
S&P 500
94.59%

Compare To: CYCC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CYCC

View More

Valuation Measures

Annual
As of 10/15/2024
  • Market Cap

    1.75M

  • Enterprise Value

    -4.25M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    18.35

  • Price/Book (mrq)

    1.75

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -102.53%

  • Return on Equity (ttm)

    -570.69%

  • Revenue (ttm)

    80k

  • Net Income Avi to Common (ttm)

    -17.61M

  • Diluted EPS (ttm)

    -15.3100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6M

  • Total Debt/Equity (mrq)

    0.50%

  • Levered Free Cash Flow (ttm)

    -7.66M

Research Analysis: CYCC

View More

Company Insights: CYCC

Research Reports: CYCC

View More

People Also Watch